Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Conditions:   Gastric Adenocarcinoma;   GastroEsophageal Cancer
Interventions:   Drug: TAS-102;   Drug: Irinotecan
Sponsors:   University of California, Irvine;   Taiho Pharmaceutical Co., Ltd.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 31, 2019 / by / in
Comments